We present a high-level framework that explains why, in practice, different pricing models calibrated to the same vanilla surface tend to produce similar valuations for exotic derivatives. Our approach acts as an overlay on the Monte Carlo infrastructure already used in banks, combining path reweighting with a conic optimisation layer without requiring any changes to existing code. This construction delivers narrow, practically model-independent price bands for exotics, reconciling front-office practice with the robust, model-independent ideas developed in the academic literature.
Marco Airoldi (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: